TEVA-LIOTHYRONINE TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LIOTHYRONINE (LIOTHYRONINE SODIUM)

Pieejams no:

TEVA CANADA LIMITED

ATĶ kods:

H03AA02

SNN (starptautisko nepatentēto nosaukumu):

LIOTHYRONINE SODIUM

Deva:

5MCG

Zāļu forma:

TABLET

Kompozīcija:

LIOTHYRONINE (LIOTHYRONINE SODIUM) 5MCG

Ievadīšanas:

ORAL

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription

Ārstniecības joma:

THYROID AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0102421001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2019-11-21

Produkta apraksts

_ _
_Teva-Liothyronine Tablets _
_Page 1 of 17_
PRODUCT MONOGRAPH
Pr
TEVA-LIOTHYRONINE
Liothyronine Sodium Tablets
5 mcg and 25 mcg liothyronine as liothyronine sodium
USP
Hypothyroidism Therapy
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Approval:
November 20, 2019
Submission Control No: 217318
_ _
_Teva-Liothyronine Tablets _
_Page 2 of 17_
TABLE OF CONTENTS
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DRUG/LABORATORY TEST INTERACTIONS
.............................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION
............................................................................................................................12
CLINICAL PHARMACOLOGY
......................................................................................12
SUPPLY
.............................................................................................................................15
COMPOSITION
................................................................................................................15
PART III: CONSUMER INFORMATION
......................................................................16
_ _
_Teva-Liothyronine Tablets _
_Page 3 of 17_
Pr
TEVA-LIOTHYRONINE
liothyronine sodium
INDICATIONS AND CLINICAL USE
TEVA-LIOTHYRONINE is